

BioCryst is shutting down all internal drug discovery and closing the Alabama research center where it was born nearly 40 years ago. The move saves $30 million, but it raises a bigger question: can a biotech company survive without actually doing biotech?
Imagine building a kitchen from scratch, cooking in it for nearly 40 years, and then one day announcing you're done making your own food. From now on, you're ordering in.
That's essentially what BioCryst Pharmaceuticals just did. On June 29, 2026, the company announced it will shut down all internal drug discovery programs and close its Discovery Center of Excellence in Birmingham, Alabama by the end of 2026. No more early-stage research. No more lab coats. The company that was literally born out of University of Alabama at Birmingham research in 1986 is walking away from the thing that made it.
The question isn't whether this is bold. It obviously is. The question is whether it's smart.
BioCryst's Birmingham facility isn't just some satellite office. It's the company's origin story. The discovery center traces back to the late 1980s, when BioCryst spun out of UAB as a structure-based drug design company. For decades, this was the engine room: the place where scientists turned molecular targets into actual medicines.
Now it's getting a closing date. The facility will wind down over the next six months, with the company describing the move as a "strategic evolution." Around 100 positions are expected to be eliminated, though BioCryst hasn't disclosed an exact headcount in its SEC filings.
The company says it will support affected employees through the transition. Cold comfort when your lab is being turned into a landlord's problem.
If you want to understand why BioCryst made this call, start with the spreadsheet. The company lowered its 2026 operating expense guidance from $450–$470 million down to $420–$440 million. That's roughly $30 million in savings, directly tied to shuttering the Birmingham operation.
And BioCryst isn't hurting for revenue. The company pulled in $874.8 million in 2025, with $263.9 million in net income. Its flagship drug, ORLADEYO (an oral pill that prevents attacks in patients with hereditary angioedema, a rare condition causing severe swelling), is a genuine commercial success. Full-year 2026 revenue guidance for ORLADEYO alone sits at $625–$645 million.

Praxis Precision Medicine's epilepsy drug just got a three-month FDA delay, and it's far from the only biotech feeling the squeeze. With roughly 3,500 FDA employees cut since 2025, the agency's review machine is straining under its own weight.


Join thousands of biotech professionals who start their day with our free, daily briefing.
So this isn't a company running out of cash and cutting costs in a panic. This is a profitable biotech choosing to stop doing something it's done since birth. That distinction matters.
BioCryst's new strategy boils down to three words: buy, don't build. Instead of running its own discovery labs, the company will source early-stage drug candidates through partnerships, licensing deals, and external collaborations. Think of it like a movie studio that stops writing original scripts and instead buys the best screenplays from independent writers.
The logic is straightforward. Early-stage drug discovery is expensive, slow, and brutally uncertain. Most programs fail. By outsourcing that risk to external partners, BioCryst can focus its capital on the stuff it's actually good at: running late-stage clinical trials and selling drugs to patients.
The company's two most important pipeline programs will continue uninterrupted. Navenibart, a long-acting antibody for hereditary angioedema, just finished enrolling its Phase 3 trial (called ALPHA-ORBIT), with results expected in Q3 2027. And BCX17725, a protein therapy for Netherton syndrome (a painful, rare skin disorder), should deliver proof-of-concept data by year-end 2026.
Neither of those came out of the Birmingham lab's recent work. Which tells you something about how BioCryst's leadership viewed the return on investment from internal discovery.
Analysts, for the most part, like the move. Jefferies maintained a Buy rating and bumped its price target to $15, calling the shift toward external innovation a more "capital-efficient R&D model." The broader read on the Street is that BioCryst is getting leaner without getting weaker.
That said, there's a quiet undercurrent of concern. If your entire future pipeline depends on finding the right partners, you're only as good as the deals you can strike. BioCryst has commercial infrastructure and rare-disease expertise to offer, but so do a dozen other mid-cap biotechs looking for the same thing. The competition for quality external assets is fierce, and licensing deals aren't cheap.
BioCryst isn't doing this in a vacuum. Across the industry, companies are increasingly outsourcing pieces of drug discovery that used to happen in-house. GSK signed a deal with Hengrui Pharma worth up to $12.5 billion for external assets. Pfizer cut an agreement worth up to $6.05 billion with 3SBio. AstraZeneca and Sanofi have both leaned into AI-enabled discovery through partnerships rather than building those capabilities internally.
But there's an important distinction. Most of those examples involve big pharma supplementing internal R&D with external deals. BioCryst is a mid-cap biotech replacing internal discovery entirely. That's a fundamentally different bet.
McKinsey has noted that the industry swings between outsourcing and insourcing like a pendulum. Some companies that aggressively outsourced are now pulling work back in-house. BioCryst is betting the pendulum won't swing back before it finds its next drug.
Let's zoom out. A company founded on the idea that it could discover drugs better than anyone else has concluded that, actually, other people can do it cheaper and faster. That's not a failure; it's an honest assessment. But it does raise a deeper question about the sustainability of small-company R&D.
Discovery research is where the magic happens. It's where a scientist stares at a protein structure and sees a drug that doesn't exist yet. When mid-cap biotechs give that up, the ecosystem loses something. The external partners and CROs picking up the slack are often excellent, but they're optimizing for efficiency, not serendipity.
BioCryst still has a healthy commercial business, strong revenue, and two promising late-stage programs. The near-term picture looks fine. The longer-term question is whether a biotech company without a discovery engine is really a biotech company at all, or just a very specialized sales organization waiting for someone else to invent the future.
For the scientists in Birmingham who spent careers turning molecules into medicines, that's more than an academic question. It's a pink slip wrapped in a press release.
Vistagen's anxiety drug fasedienol just went 1-for-3 in Phase 3 trials, torching 80% of the stock's value. The company is betting a post-hoc subgroup signal and an FDA meeting can save a program that Wall Street has all but written off.